黄芪丹参滴丸治疗冠心病心绞痛(气虚血瘀证)的临床疗效  

Efficacy and safety of Astragalus mongholicus-Salvia drop pills(ASDP) in patients with angina pectoris

作　　者：毛静远[1] 郑颖[1] 王化良[1] 王强[1] 李红[1] 张运[1] 张其梅[1] 吴慧轩[1] 常延平[1] 虞东玲[1] 张宇[1] 王恒和[1] 

机构地区：[1]天津中医药大学第一附属医院心内科,天津300193

出　　处：《中国新药杂志》2007年第3期244-247,共4页Chinese Journal of New Drugs

摘　　要：目的:评价黄芪丹参滴丸治疗冠心病心绞痛(气虚血瘀证)的有效性和安全性。方法:采用双模拟、平行对照法。冠心病心绞痛患者189例随机分为试验组131例(脱落2例)和对照组58例。试验组口服黄芪丹参滴丸和养心氏片模拟剂,对照组口服养心氏片和黄芪丹参滴丸模拟剂。治疗4周后观察患者的临床症状、心电图及血液流变学等指标变化。结果:试验组和对照组的心绞痛总有效率分别为90.70%和75.87%(P<0.05)。两组心电图均较治疗前显著改善,试验组和对照组的心电图总有效率分别为62.79%和56.90%(P>0.05)。试验组和对照组的硝酸甘油停减率分别为85.09%和77.78%(P>0.05)。未见明显不良反应,对患者肝肾功能等亦无明显影响。结论:黄芪丹参滴丸治疗冠心病心绞痛(气虚血瘀证)安全、有效。Objective：To evaluate the efficacy and safety of Astragalus mongholicus-Salvia drop pills（ASDP） in the patients with coronary artery disease angina pectoris （syndrome of deficiency of vital energy and blood stasis）. Method：Totally 189 patients coincide with the criterion of coronary artery disease angina pectoris were randomly assigned to two groups： the treating group with ASDP and the placebo of YangXinShi pill（YXSP） （n = 131 ） and the control one with YXSP and the placebo of ASDP （n =58） for 4 weeks. The efficacy was assessed based on improvement of clinical symptoms and signs, ECG and blood rheology. Results： The total efficacy rate in the treating group and the control one was 90.70% vs. 75.87% （P〈0.05）. The ECGimprovement rate was 62.79% vs. 56.90% （P〉0.05）; and the rate of Nitroglycerin termination or reduction was 85.09% vs. 77.78% （P 〉 0.05）. No adverse reactions and effect in hepatorenal function were reported. Conclusion：ASDP offered an effective and safe traditional Chinese medicine preparation for the patients with artery disease angina pectoris （syndrome of deficiency of vital energy and blood stasis）.

关 键 词：黄芪丹参滴丸 气虚血瘀证 冠心病 心绞痛 

分 类 号：R541.4[医药卫生—心血管疾病] R972.3[医药卫生—内科学]